IASIS PHARMA proudly announces the addition of Glucofree^® & Glucoplus^® to its wide product portfolio.

Glucofree^® & Glucoplus^® have metformin hydrochloride as their active ingredient and they belong to OHAs (Oral Hypoglycemic Agents).

Metformin’s therapeutic indication is type 2 diabetes, especially on obese patients when the imposed diet and body exercise are not enough to restore their glycemic index. It is a substance with many years of well-established use and low therapy cost.

Glucofree^® & Glucoplus^® can be used to adults as a monotherapy or in combination with other oral anti-diabetic agents or insulin. To children (>10 years old) and adolescents, they can also be used as monotherapy or in combination with insulin.

Metformin has anti-hyperglycemic actions, thereby reducing both fasting and postprandial glucose. It does not trigger insulin secretion, therefore it does not produce hypoglycemia. In addition, when metformin is prescripted as a monotherapy, it is linked either with maintaining body weight levels, or with mild weight loss. Beside its action against glycemia, metformin also has beneficial effects in metabolizing lipids, as it reduces cholesterol, LDL cholesterol and triglycerides.

Glucofree® is distributed in film-coated tablets, each containing 850 mg metformin hydrochloride, in packages of 60 f.c.tabs.

Glucoplus® is distributed in film-coated tablets, each containing 1000 mg metformin hydrochloride, in packages of 30 f.c.tabs.